Security key
03828A101
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (APLT)
CUSIP: 03828A101
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 106,044,815
- Total 13F value
- $51,845,704
- Share change
- -8,856,390
- Put/Call ratio
- 94%
- SEC-reported price per share
- $0.49
- Number of holders
- 89
- Value change
- -$6,334,916
- Number of buys
- 38
- Number of sells
- 70
- Shares outstanding
- 143,223,667
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
89
Top holders
10
APLT full security history
Ownership snapshot
Full 13F holder table
KalVista Pharmaceuticals, Inc. SEC filings
KalVista Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of APLT - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Capital World Investors
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
Lead comparable stake: 6.4%
13D/G row: Capital World Investors
Showing 1-6 of 15 holder rows.
Quick read
Capital World Investors leads the comparable SEC ownership view at 6.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Capital World Investors's linked filing trail.
Comparable ownership
Top 5
Capital World Investors
6.4%
SUVRETTA CAPITAL MANAGEMENT, LLC
9.2%
Frazier Life Sciences Management,...
9.2%
Propel Bio Management, LLC
6.7%
Schonfeld Strategic Advisors LLC
6.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Capital World Investors |
13D/G
13F
Company
|
6.4%
|
$40,927,321
3,177,587 shares
|
$0 | 31 Mar 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
Company
|
9.2%
|
$41,613,212
4,913,012 shares
|
— | 31 Dec 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
9.2%
|
$41,400,233
4,887,867 shares
|
— | 31 Dec 2024 |
| Propel Bio Management, LLC |
13F
Company
|
6.7%
|
$8,232,723
9,615,420 shares
|
— | 31 Dec 2024 |
| Schonfeld Strategic Advisors LLC |
13F
Company
|
6.1%
|
$7,502,272
8,762,291 shares
|
— | 31 Dec 2024 |
| Knoll Capital Management, LLC |
13F
Company
|
4%
|
$4,964,532
5,799,687 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
89
Shares
106,044,815
Rows available
89
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
89
Q1 2025 holders
89
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|